NeuClone is a clinical-stage biopharmaceutical company with an exclusive focus on the development and commercialisation of high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at a scale and price that meets demands of global markets. NeuClone is differentiated by this unmatched pipeline, and a trademark Right From the Start® approach – through which we continually confirm biosimilarity at the earliest stages and throughout development.
